Preferred partner for industry collaboration

monash.edu/discovery-institute
WHO WE ARE
An institute with the scale and scope to tackle major research questions.

We are one of the largest and highest-quality biomedical research institutes in Australia. With more than 120 internationally-renowned research teams, we work with national and international collaborators on global health priorities.

WHAT WE DO
Discover and innovate to enhance lives.

Our scientists are passionate about discovery research and committed to establishing a culture of excellence and collaboration to enable the most important research questions to be addressed.

With strong international networks and partnerships with researchers, health precincts and industry, together with access to unparalleled, world-leading research infrastructure, our discoveries accelerate the ability to prevent, diagnose and treat disease.

DISCOVER
Pursue excellence in discovery research within and across these six global health priority areas:
- Cancer
- Cardiovascular Disease
- Development and Stem Cells
- Infection and Immunity
- Metabolic Disease and Obesity
- Neuroscience

TRANSLATE
Translate and commercialise our research to impact on health outcomes.

COLLABORATE AND CONNECT
Collaborate globally to conduct outstanding research.

DEVELOP OUR PEOPLE
Attract and develop the science leaders of the future in a diverse and supportive environment.

ENGAGE
Engage with the wider community in all that we do, to inform, influence and advocate.

WE HAVE A GREAT STORY TO TELL INDUSTRY, A GROWING PIPELINE OF DISCOVERIES, AND THE RIGHT PEOPLE AND PLATFORMS FOR COLLABORATION.

FAST FACTS
- 700+ PUBLICATIONS PER YEAR
- $50m ANNUAL RESEARCH INCOME
- $14m INDUSTRY FUNDING
- 200+ INTERNATIONAL RESEARCH COLLABORATORS
- TOP 50 TIMES HIGHER EDUCATION WORLD RANKING 2015/16
- 700+ RESEARCHERS
- 120+ RESEARCH GROUPS
- 700 RESEARCHERS
- 200+ INTERNATIONAL RESEARCH COLLABORATORS
- 729 PhD STUDENTS
Monash Biomedicine Discovery Institute

Monash University is in pole position to accelerate the commercialisation of our breakthroughs globally. Its long track record of commercialising technology and discoveries to bring new products and services to the market includes the world-famous Monash IVF and flu treatment Relenza™.

At the Monash Biomedicine Discovery Institute, we’re working with leading pharmaceutical and biotechnology companies to develop our discoveries, with close to 20 potential therapies in the pipeline. We want our research to deliver even greater benefits to society and solve unmet medical needs. To that end, we have already partnered some of our most promising research with leading biotechnology companies such as Regeneron, Janssen, Roche, GSK, as well as Pfizer CTI.

Monash’s state-of-the-art integrated platform technologies has also attracted local small and medium enterprises, such as Trajan and MiniFab and international corporations like CSL, Tecan, MedImmune and others.

We encourage you to get in touch with us to find out how we can work together.

Monash has entered into a multi-year research and commercialisation agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the early detection and prevention of rheumatoid arthritis.

Rheumatoid arthritis is a debilitating autoimmune disease that affects more than 400,000 Australians and more than 24.5 million people worldwide.

The Monash-based researchers, led by ARC Laureate Fellow Professor Jamie Rossjohn, have been investigating the impact of therapeutics on immune systems affected by rheumatoid arthritis. Collaborations such as this are accelerated by our proximity to major biomedical research infrastructure such as the Australian Synchrotron, Monash Biomedical Imaging and other research facilities such as CSIRO.

The collaboration between the Monash Biomedicine Discovery Institute and Janssen brings together world-class research excellence and industry expertise to deliver health benefits on a global scale. It is another example of how we are actively engaging with industry in order to translate our world-leading research into a pipeline of medical breakthroughs.
OUR THERAPEUTIC PIPELINE

Researchers from the Monash Biomedicine Discovery Institute have built a rich pipeline of translatable biomedical discoveries, from novel targets to biologics and drug candidates across a range of therapeutic indications that are available for partnering. Check out our pipeline and replenish yours.

<table>
<thead>
<tr>
<th>THERAPY AREA</th>
<th>DISCOVERY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CANCER</strong></td>
<td>IL-21 mAb agonist</td>
</tr>
<tr>
<td></td>
<td>ADAM10 mAb</td>
</tr>
<tr>
<td></td>
<td>Adoptive cell therapy/CAR-T</td>
</tr>
<tr>
<td></td>
<td>Grb7 inhibitors</td>
</tr>
<tr>
<td></td>
<td>Prostate cancer</td>
</tr>
<tr>
<td><strong>CARDIO-VASCULAR DISEASE</strong></td>
<td>Selective AT2 receptor agonists (peptides)</td>
</tr>
<tr>
<td></td>
<td>Novel target (small molecule)</td>
</tr>
<tr>
<td><strong>INFECTION &amp; IMMUNITY</strong></td>
<td>Antibiotic/anti-sporulation – C. diff</td>
</tr>
<tr>
<td></td>
<td>Anti-virals (nuclear transport)</td>
</tr>
<tr>
<td></td>
<td>Aminopeptidase inhibitors</td>
</tr>
<tr>
<td></td>
<td>MicroCube – bioengineered protein crystals containing antigens</td>
</tr>
<tr>
<td><strong>METABOLIC DISEASES &amp; OBESITY</strong></td>
<td>T2DM</td>
</tr>
<tr>
<td></td>
<td>Obesity</td>
</tr>
</tbody>
</table>

Produced by Strategic Marketing and Communications, Monash University, 17P-0959. August 2017. CRICOS provider: Monash University 00008C

Monash has joined the Science in Australia Gender Equity pilot of the Athena SWAN program.